Atrial Fibrillation with the AliveCor KardiaMobile

Improving the utility and sustainability of novel health technology to improve clinical outcomes for patients: an East Staffordshire experience of screening for atrial fibrillation with the AliveCor KardiaMobile

The results of this study show a positive impact on the diagnosis and management of AF using AliveCor KardiaMobile devices in East Staffordshire. Not only have they contributed to improved patient outcomes, with 49 new diagnoses of AF in otherwise asymptomatic patients, but they also have widespread acceptance and are valued by the clinicians utilising them. These findings are in keeping with other studies that have reported similar value in utilising AliveCor KardiaMobile in the detection of AF, and with European Society of Cardiology guidelines that recommend opportunistic screening for AF in patients ≥65 years of age.